In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Role of the Sodium/Glutamate Blocker Riluzole in Enhancing Functional Outcomes in Patient Undergoing Surgery for Degenerative Cervical Myelopathy: Results of the Prospective, Multicentre Double Blind

    Final Number:
    172

    Authors:
    M. Fehlings; B. Kopjar; H. Ahn; F. Farhadi; C. Shaffrey; A. Nassr; P. Mummaneni; P. Arnold; B. Jacobs; K. Riew; D. Brodke; A. Vaccaro; A. Hilibrand; J. Wilson; J. Harrop; S. Yoon; K. Kim; D. Fourney; C. Santaguida

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: Degenerative cervical myelopathy (DCM), which encompasses cervical spondylotic myelopathy and ossification of the posterior longitudinal ligament, is the most common cause of spinal cord impairment. Decompressive surgery is the most effective treatment, however, most patients are left with residual neurological impairment and some experience neurological decline. Based on strong preclinical basic science evidence and collateral evidence from trials in human spinal cord injury and amyotrophic lateral sclerosis, we sought to explore if the sodium-glutamate antagonist riluzole would enhance neurological recovery and reduce perioperative neurological decline.

    Methods: This is a phase III multi-center, double-blind, placebo-controlled, randomized controlled trial. Between March 2012 and June 2017, 300 surgically naive patients with moderate to severe DCM were enrolled at 16 sites. Subjects were randomized 1:1 to either the 50 mg riluzole bid or placebo-controlled group, beginning the medications at 14 days pre-surgery and ending at 28 days post-operative. Follow-up was at 6- and 12-months to determine the primary endpoint, change in mJOA scores; and the secondary endpoints, change in SF-36v2, Neck Disability Index (NDI), Nurick grade, EQ-5D, ASIA motor and sensory scores, Bazaz scale, Visual Analog Scale (VAS) for Pain, grip strength and neurological compilations.

    Results: The average age was 57.9 years (SD 10.2); 55.7% males; 80.1% white; 9.7% black. Baseline mJOA score was 11.84 (SD 1.5, range 8 to 14); Nurick grade was 3.3 (SD 0.8); NDI 42.9 (SD 13.5); VAS arm/shoulder 4.7 (SD 2.9); VAS neck 4.9 (SD 3.0). The study will complete in December 2017 with a projected follow-up rate exceeding 90%. Efficacy results will be available and presented at the conference.

    Conclusions: This study contributes Level I evidence concerning efficacy and safety of riluzole as an adjunct therapy to decompressive surgery for patients with DCM.

    Patient Care: The aim of this study is to explore if the sodium-glutamate antagonist riluzole would enhance neurological recovery and reduce perioperative neurological decline.

    Learning Objectives: The aim of this study is to explore if the sodium-glutamate antagonist riluzole would enhance neurological recovery and reduce perioperative neurological decline.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy